Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Trastuzumab + Varlitinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 47||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Varlitinib||ARRY-334543|ARRY-543||EGFR Inhibitor (Pan) 47 HER2 Inhibitor 25||Varlitinib is a selective inhibitor of EGFR and ERBB2 (HER2), which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation and increased cell death (PMID: 30658422).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 over exp||stomach cancer||sensitive||Trastuzumab + Varlitinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|